<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="44384"><DrugName>ceftriaxone</DrugName><DrugNamesKey><Name id="42995823">Rocefalin</Name><Name id="43057152">Rocefin</Name><Name id="42861373">Rocephin</Name><Name id="42754775">ceftriaxone</Name></DrugNamesKey><DrugSynonyms><Name><Value>ceftriaxone</Value><Types><Type>INN</Type></Types></Name><Name><Value>ceftriaxone sodium</Value></Name><Name><Value>Rocephin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Rocefalin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Rocefin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>73384-59-5</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>74578-69-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19446">Roche Holding AG</CompanyOriginator><CompaniesPrimary><Company id="19446">Roche Holding AG</Company><Company id="1137333">Taiyo Pharmaceuticals Industry</Company></CompaniesPrimary><CompaniesSecondary><Company id="15414">Chugai Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="44384" type="Drug"><TargetEntity id="91136" type="siDrug">Ceftriaxone sodium</TargetEntity></SourceEntity><SourceEntity id="15414" type="Company"><TargetEntity id="4295876884" type="organizationId">Chugai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="1061" type="ciIndication"><TargetEntity id="10040753" type="MEDDRA"></TargetEntity><TargetEntity id="D012852" type="MeSH"></TargetEntity><TargetEntity id="-2064751732" type="omicsDisease"></TargetEntity><TargetEntity id="302" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1075" type="ciIndication"><TargetEntity id="10061190" type="MEDDRA"></TargetEntity><TargetEntity id="D006192" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="114" type="ciIndication"><TargetEntity id="10040047" type="MEDDRA"></TargetEntity><TargetEntity id="D018805" type="MeSH"></TargetEntity><TargetEntity id="-200243460" type="omicsDisease"></TargetEntity><TargetEntity id="953" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="116" type="ciIndication"><TargetEntity id="10051910" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="120" type="ciIndication"><TargetEntity id="D004927" type="MeSH"></TargetEntity><TargetEntity id="-1969770508" type="omicsDisease"></TargetEntity><TargetEntity id="803" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1393" type="ciIndication"><TargetEntity id="10058890" type="MEDDRA"></TargetEntity><TargetEntity id="D001442" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="1434" type="ciIndication"><TargetEntity id="10051904" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1437" type="ciIndication"><TargetEntity id="10054876" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1438" type="ciIndication"><TargetEntity id="10061470" type="MEDDRA"></TargetEntity><TargetEntity id="D011512" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="1440" type="ciIndication"><TargetEntity id="10061512" type="MEDDRA"></TargetEntity><TargetEntity id="D016868" type="MeSH"></TargetEntity><TargetEntity id="-311564119" type="omicsDisease"></TargetEntity><TargetEntity id="4021" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="145" type="ciIndication"><TargetEntity id="1410" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1453" type="ciIndication"><TargetEntity id="10051894" type="MEDDRA"></TargetEntity><TargetEntity id="D000151" type="MeSH"></TargetEntity><TargetEntity id="-1718351203" type="omicsDisease"></TargetEntity><TargetEntity id="5131" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1475" type="ciIndication"><TargetEntity id="A38" type="ICD10"></TargetEntity><TargetEntity id="034.1" type="ICD9"></TargetEntity></SourceEntity><SourceEntity id="1484" type="ciIndication"><TargetEntity id="10060693" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1487" type="ciIndication"><TargetEntity id="J20" type="ICD10"></TargetEntity><TargetEntity id="466.0" type="ICD9"></TargetEntity><TargetEntity id="279" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1503" type="ciIndication"><TargetEntity id="10036774" type="MEDDRA"></TargetEntity><TargetEntity id="D011349" type="MeSH"></TargetEntity><TargetEntity id="-1241670668" type="omicsDisease"></TargetEntity><TargetEntity id="3623" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1796" type="ciIndication"><TargetEntity id="N45.1" type="ICD10"></TargetEntity><TargetEntity id="10015000" type="MEDDRA"></TargetEntity><TargetEntity id="D004823" type="MeSH"></TargetEntity><TargetEntity id="-1202326299" type="omicsDisease"></TargetEntity><TargetEntity id="4378" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1798" type="ciIndication"><TargetEntity id="10054088" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1803" type="ciIndication"><TargetEntity id="G00" type="ICD10"></TargetEntity><TargetEntity id="320" type="ICD9"></TargetEntity><TargetEntity id="10027202" type="MEDDRA"></TargetEntity><TargetEntity id="D016920" type="MeSH"></TargetEntity><TargetEntity id="-373187665" type="omicsDisease"></TargetEntity><TargetEntity id="893" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1815" type="ciIndication"><TargetEntity id="J15" type="ICD10"></TargetEntity><TargetEntity id="10060946" type="MEDDRA"></TargetEntity><TargetEntity id="D018410" type="MeSH"></TargetEntity><TargetEntity id="-2031977293" type="omicsDisease"></TargetEntity><TargetEntity id="928" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="195" type="ciIndication"><TargetEntity id="4198" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2019" type="ciIndication"><TargetEntity id="K81" type="ICD10"></TargetEntity><TargetEntity id="10008612" type="MEDDRA"></TargetEntity><TargetEntity id="D002764" type="MeSH"></TargetEntity><TargetEntity id="-1275543177" type="omicsDisease"></TargetEntity><TargetEntity id="437" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2216" type="ciIndication"><TargetEntity id="K83.0" type="ICD10"></TargetEntity><TargetEntity id="10008604" type="MEDDRA"></TargetEntity><TargetEntity id="D002761" type="MeSH"></TargetEntity><TargetEntity id="-484690873" type="omicsDisease"></TargetEntity><TargetEntity id="435" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="227" type="ciIndication"><TargetEntity id="A54" type="ICD10"></TargetEntity><TargetEntity id="10018612" type="MEDDRA"></TargetEntity><TargetEntity id="D006069" type="MeSH"></TargetEntity><TargetEntity id="-1597924426" type="omicsDisease"></TargetEntity><TargetEntity id="914" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2339" type="ciIndication"><TargetEntity id="10023874" type="MEDDRA"></TargetEntity><TargetEntity id="D007827" type="MeSH"></TargetEntity><TargetEntity id="-499701933" type="omicsDisease"></TargetEntity><TargetEntity id="3449" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2345" type="ciIndication"><TargetEntity id="10044008" type="MEDDRA"></TargetEntity><TargetEntity id="D014069" type="MeSH"></TargetEntity><TargetEntity id="-68262349" type="omicsDisease"></TargetEntity><TargetEntity id="956" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2437" type="ciIndication"><TargetEntity id="10014568" type="MEDDRA"></TargetEntity><TargetEntity id="D004653" type="MeSH"></TargetEntity><TargetEntity id="-1888969151" type="omicsDisease"></TargetEntity><TargetEntity id="2490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2525" type="ciIndication"><TargetEntity id="L03" type="ICD10"></TargetEntity><TargetEntity id="10007882" type="MEDDRA"></TargetEntity><TargetEntity id="D002481" type="MeSH"></TargetEntity><TargetEntity id="-616611590" type="omicsDisease"></TargetEntity><TargetEntity id="453" type="siCondition"></TargetEntity><TargetEntity id="3914" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="280" type="ciIndication"><TargetEntity id="804" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="284" type="ciIndication"><TargetEntity id="10037596" type="MEDDRA"></TargetEntity><TargetEntity id="D011704" type="MeSH"></TargetEntity><TargetEntity id="-721934222" type="omicsDisease"></TargetEntity><TargetEntity id="344" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2951" type="ciIndication"><TargetEntity id="10046480" type="MEDDRA"></TargetEntity><TargetEntity id="D014526" type="MeSH"></TargetEntity><TargetEntity id="-1620155457" type="omicsDisease"></TargetEntity><TargetEntity id="917" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="308" type="ciIndication"><TargetEntity id="4176" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3081" type="ciIndication"><TargetEntity id="10000269" type="MEDDRA"></TargetEntity><TargetEntity id="D000038" type="MeSH"></TargetEntity><TargetEntity id="-473240105" type="omicsDisease"></TargetEntity><TargetEntity id="870" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="309" type="ciIndication"><TargetEntity id="10058080" type="MEDDRA"></TargetEntity><TargetEntity id="D013203" type="MeSH"></TargetEntity><TargetEntity id="-967239129" type="omicsDisease"></TargetEntity><TargetEntity id="812" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="312" type="ciIndication"><TargetEntity id="10061372" type="MEDDRA"></TargetEntity><TargetEntity id="D013290" type="MeSH"></TargetEntity><TargetEntity id="-669221578" type="omicsDisease"></TargetEntity><TargetEntity id="814" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3140" type="ciIndication"><TargetEntity id="10034254" type="MEDDRA"></TargetEntity><TargetEntity id="D000292" type="MeSH"></TargetEntity><TargetEntity id="-856114132" type="omicsDisease"></TargetEntity><TargetEntity id="1756" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3653" type="ciIndication"><TargetEntity id="10062233" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="3819" type="ciIndication"><TargetEntity id="10004142" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="3820" type="ciIndication"><TargetEntity id="N72" type="ICD10"></TargetEntity><TargetEntity id="10008323" type="MEDDRA"></TargetEntity><TargetEntity id="D002575" type="MeSH"></TargetEntity><TargetEntity id="-1640821943" type="omicsDisease"></TargetEntity><TargetEntity id="910" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3886" type="ciIndication"><TargetEntity id="10025028" type="MEDDRA"></TargetEntity><TargetEntity id="D008169" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="394" type="ciIndication"><TargetEntity id="10033078" type="MEDDRA"></TargetEntity><TargetEntity id="D010033" type="MeSH"></TargetEntity><TargetEntity id="-2113735649" type="omicsDisease"></TargetEntity><TargetEntity id="898" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"></TargetEntity><TargetEntity id="10060945" type="MEDDRA"></TargetEntity><TargetEntity id="D001424" type="MeSH"></TargetEntity><TargetEntity id="-1693440076" type="omicsDisease"></TargetEntity><TargetEntity id="800" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="403" type="ciIndication"><TargetEntity id="N30" type="ICD10"></TargetEntity><TargetEntity id="10011781" type="MEDDRA"></TargetEntity><TargetEntity id="D003556" type="MeSH"></TargetEntity><TargetEntity id="-1776447469" type="omicsDisease"></TargetEntity><TargetEntity id="941" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="428" type="ciIndication"><TargetEntity id="D003015" type="MeSH"></TargetEntity><TargetEntity id="-1973220469" type="omicsDisease"></TargetEntity><TargetEntity id="815" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="452" type="ciIndication"><TargetEntity id="K65" type="ICD10"></TargetEntity><TargetEntity id="10034674" type="MEDDRA"></TargetEntity><TargetEntity id="D010538" type="MeSH"></TargetEntity><TargetEntity id="-1837137483" type="omicsDisease"></TargetEntity><TargetEntity id="2483" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="453" type="ciIndication"><TargetEntity id="10034835" type="MEDDRA"></TargetEntity><TargetEntity id="D010612" type="MeSH"></TargetEntity><TargetEntity id="-936863937" type="omicsDisease"></TargetEntity><TargetEntity id="2978" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="456" type="ciIndication"><TargetEntity id="4196" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="485" type="ciIndication"><TargetEntity id="D017192" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="554" type="ciIndication"><TargetEntity id="10005941" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="573" type="ciIndication"><TargetEntity id="H16.0" type="ICD10"></TargetEntity><TargetEntity id="D003320" type="MeSH"></TargetEntity><TargetEntity id="-1247959915" type="omicsDisease"></TargetEntity><TargetEntity id="771" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="638" type="ciIndication"><TargetEntity id="10061259" type="MEDDRA"></TargetEntity><TargetEntity id="D007710" type="MeSH"></TargetEntity><TargetEntity id="-801568713" type="omicsDisease"></TargetEntity><TargetEntity id="4174" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="706" type="ciIndication"><TargetEntity id="10036898" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bacterial infection - Switzerland - Dec-1982</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1061">Sinusitis</Indication><Indication id="114">Sepsis</Indication><Indication id="116">Enterobacter infection</Indication><Indication id="120">Escherichia coli infection</Indication><Indication id="1393">Bacteroides infection</Indication><Indication id="1434">Citrobacter infection</Indication><Indication id="1438">Proteus infection</Indication><Indication id="1439">Providencia infection</Indication><Indication id="1440">Serratia infection</Indication><Indication id="145">Haemophilus influenzae infection</Indication><Indication id="1484">Bacterial respiratory tract infection</Indication><Indication id="1487">Acute bronchitis</Indication><Indication id="1503">Proctitis</Indication><Indication id="1796">Epididymitis</Indication><Indication id="1798">Bacterial urinary tract infection</Indication><Indication id="1803">Bacterial meningitis</Indication><Indication id="1815">Bacterial pneumonia</Indication><Indication id="2019">Cholecystitis</Indication><Indication id="2216">Cholangitis</Indication><Indication id="227">Neisseria gonorrhoeae infection</Indication><Indication id="2339">Laryngitis</Indication><Indication id="2345">Tonsillitis</Indication><Indication id="2437">Empyema</Indication><Indication id="2525">Cellulitis</Indication><Indication id="284">Pyelonephritis</Indication><Indication id="2951">Urethritis</Indication><Indication id="3081">Abscess</Indication><Indication id="309">Staphylococcus infection</Indication><Indication id="312">Streptococcus infection</Indication><Indication id="313">Streptococcus pneumoniae infection</Indication><Indication id="3140">Pelvic inflammatory disease</Indication><Indication id="3263">Morganella morganii infection</Indication><Indication id="3314">Prevotella infection</Indication><Indication id="3653">Uterus infection</Indication><Indication id="3819">Bartholinitis</Indication><Indication id="3820">Cervicitis</Indication><Indication id="3886">Lung abscess</Indication><Indication id="394">Otitis media</Indication><Indication id="40">Bacterial infection</Indication><Indication id="403">Cystitis</Indication><Indication id="452">Peritonitis</Indication><Indication id="453">Pharyngitis</Indication><Indication id="485">Bacterial skin infection</Indication><Indication id="554">Bone and joint infection</Indication><Indication id="573">Corneal ulcer</Indication><Indication id="638">Klebsiella infection</Indication><Indication id="706">Prophylaxis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1075">Haemophilus infection</Indication><Indication id="1394">Bacteroides fragilis infection</Indication><Indication id="1437">Morganella infection</Indication><Indication id="1453">Acinetobacter infection</Indication><Indication id="1455">Moraxella catarrhalis infection</Indication><Indication id="1475">Streptococcus pyogenes infection</Indication><Indication id="1811">Neisseria meningitidis meningitis</Indication><Indication id="195">Klebsiella pneumoniae infection</Indication><Indication id="280">Pseudomonas aeruginosa infection</Indication><Indication id="308">Staphylococcus aureus infection</Indication><Indication id="428">Clostridium infection</Indication><Indication id="456">Proteus mirabilis infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="1594">Antibacterial</Action><Action id="104">Bacterial cell wall synthesis inhibitor</Action><Action id="15187">Systemic dermatological antibacterial product</Action><Action id="1537">Cephalosporin</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="66">Antibiotic</Technology><Technology id="740">Infusion</Technology><Technology id="746">Solution</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra><Ephmra><Code>J1D</Code><Name>CEPHALOSPORINS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-03-29T11:27:29.000Z</LastModificationDate><ChangeDateLast>2019-01-29T00:00:00.000Z</ChangeDateLast><AddedDate>2003-03-26T18:05:41.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt; has developed and launched ceftriaxone (Rocephin; Rocefalin; Rocefin), a third-generation, semisynthetic cephalosporin for iv and im administration. In the UK, ceftriaxone is indicated for the treatment of pneumonia, septicemia, meningitis, bone, skin and soft tissue infections, infections in neutropenic patients, gonorrhea, and for the peri-operative prophylaxis of surgery-associated infections [&lt;ulink linkID="1128105" linkType="Reference"&gt;1128105&lt;/ulink&gt;]. In Japan, the drug is indicated for the treatment of sepsis, laryngitis, pharyngitis, tonsillitis, acute bronchitis, pneumonia, lung abscess, empyema, chronic respiratory disease, cystitis, pyelonephritis, epididymitis, urethritis, cervicitis, pelvic inflammatory disease, proctitis, peritonitis, intra-abdominal abscess, cholecystitis, cholangitis, bartholinitis, intrauterine infection, uterine adnexitis, purulent meningitis, corneal  inflammation (including corneal ulcer), otitis media, sinusitis, cellulitis and inflammation of the jaw due to infections caused by Staphylococcus species, Streptococcus species (including Streptococcus pneumoniae), Neisseria gonorrhoeae, Escherichia coli, Citrobacter species, Klebsiella species, Enterobacter species, Serratia species, Proteus species, Morganella morganii, Providencia species, Haemophilus influenzae, Bacteroides species, and Prevotella species [&lt;ulink linkID="1342132" linkType="Reference"&gt;1342132&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Ceftriaxone was  first launched in Switzerland in 1982, followed by Ireland, Austria and Germany in 1983 [&lt;ulink linkID="1128379" linkType="Reference"&gt;1128379&lt;/ulink&gt;], [&lt;ulink linkID="1342122" linkType="Reference"&gt;1342122&lt;/ulink&gt;]. In June 1985, the drug was launched in the US  [&lt;ulink linkID="949289" linkType="Reference"&gt;949289&lt;/ulink&gt;]; however, in March 2011, the drug was withdrawn from sale in the US for reasons other than effectiveness or safety [&lt;ulink linkID="2033650" linkType="Reference"&gt;2033650&lt;/ulink&gt;], [&lt;ulink linkID="2033651" linkType="Reference"&gt;2033651&lt;/ulink&gt;]. In August 1986, it was launched in Japan  [&lt;ulink linkID="853283" linkType="Reference"&gt;853283&lt;/ulink&gt;], [&lt;ulink linkID="1342132" linkType="Reference"&gt;1342132&lt;/ulink&gt;]. By June 2004, ceftriaxone had been approved in Japan for the additional indications of infections caused by N gonorrhoeae, pharyngitis, urethritis, cervicitis, pelvic inflammatory disease, epididymitis and rectitis [&lt;ulink linkID="561384" linkType="Reference"&gt;561384&lt;/ulink&gt;]. In November 2007, iv ceftriaxone was granted Japanese approval for the once daily treatment of pediatric patients [&lt;ulink linkID="853283" linkType="Reference"&gt;853283&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;A US patent extension was secured from 2000 to 2005 following purchase of a patent license from &lt;ulink linkID="25224" linkType="Company"&gt;Hoechst Marion Roussel&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1010293" linkType="Company"&gt;Hospira Inc&lt;/ulink&gt; and  &lt;ulink linkID="28696" linkType="Company"&gt;Sandoz&lt;/ulink&gt;  launched generic versions in the US in July 2005 [&lt;ulink linkID="613187" linkType="Reference"&gt;613187&lt;/ulink&gt;], [&lt;ulink linkID="612894" linkType="Reference"&gt;612894&lt;/ulink&gt;]. In September 2006, &lt;ulink linkID="21932" linkType="Company"&gt;Lupin&lt;/ulink&gt; received FDA approval for 10 g vials of generic ceftriaxone, having previously launched 250 mg, 500 mg, 1 g and 2 g strengths in July 2005 [&lt;ulink linkID="690389" linkType="Reference"&gt;690389&lt;/ulink&gt;]. In December 2007, &lt;ulink linkID="20348" linkType="Company"&gt;Teva Pharmaceutical&lt;/ulink&gt; launched its generic version of the product [&lt;ulink linkID="883031" linkType="Reference"&gt;883031&lt;/ulink&gt;]. &lt;ulink linkID="28997" linkType="Company"&gt;Hanmi Pharmaceutical&lt;/ulink&gt; was granted US generic approval in February 2008 [&lt;ulink linkID="875841" linkType="Reference"&gt;875841&lt;/ulink&gt;]. In July 2008, &lt;ulink linkID="1034907" linkType="Company"&gt;Sagent Pharmaceuticals&lt;/ulink&gt; launched generic ceftriaxone for injection in the US [&lt;ulink linkID="925665" linkType="Reference"&gt;925665&lt;/ulink&gt;]. In July 2009, &lt;ulink linkID="DOL1000008" linkType="Company"&gt;Ben Venue Laboratories&lt;/ulink&gt; announced that it had received FDA approval to begin shipment of   generic ceftriaxone for injection (250,  500 mg, 1 and 2 g) [&lt;ulink linkID="1026187" linkType="Reference"&gt;1026187&lt;/ulink&gt;]. In January 2013, &lt;ulink linkID="30808" linkType="Company"&gt;Strides Arcolab&lt;/ulink&gt; was granted FDA approval for its generic 10 mg ceftriaxone injection [&lt;ulink linkID="1390456" linkType="Reference"&gt;1390456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;Patent protection has expired in the EU and the product has had generic competition in Germany and France since 2001; the patent expired in Italy, its second largest market, in December 2003. Pediatric extensions took coverage to July 2005 [&lt;ulink linkID="556141" linkType="Reference"&gt;556141&lt;/ulink&gt;], [&lt;ulink linkID="520947" linkType="Reference"&gt;520947&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;In April 2013, &lt;ulink linkID="1077742" linkType="Company"&gt;Rafarm Pharmaceuticals&lt;/ulink&gt; registered a generic version of ceftriaxone in Russia as a medication under international unpatented label [&lt;ulink linkID="1400875" linkType="Reference"&gt;1400875&lt;/ulink&gt;]. &lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;Ceftriaxone was approved in the US in December 1984 and was launched during 1H85 [&lt;ulink linkID="949289" linkType="Reference"&gt;949289&lt;/ulink&gt;]; however, in March 2011, the drug was withdrawn from sale in the US for reasons other than effectiveness or safety [&lt;ulink linkID="2033650" linkType="Reference"&gt;2033650&lt;/ulink&gt;], [&lt;ulink linkID="2033651" linkType="Reference"&gt;2033651&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;Ceftriaxone was approved in Switzerland in May 1982, and launched later that year. The product was launched in Ireland, Austria and Germany in 1983 [&lt;ulink linkID="1128379" linkType="Reference"&gt;1128379&lt;/ulink&gt;], [&lt;ulink linkID="1342122" linkType="Reference"&gt;1342122&lt;/ulink&gt;]. In March 1984, the drug was approved in France, and the launch took place in March 1985 [&lt;ulink linkID="1348407" linkType="Reference"&gt;1348407&lt;/ulink&gt;]. In April 1985, the drug was launched in Portugal [&lt;ulink linkID="1366675" linkType="Reference"&gt;1366675&lt;/ulink&gt;]. In March 1986, ceftriaxone was approved in Spain; however, the marketing authorization was cancelled in May 2009 [&lt;ulink linkID="1342124" linkType="Reference"&gt;1342124&lt;/ulink&gt;]. The product was approved in the UK in September 1988; it is assumed that launch occurred shortly after approval [&lt;ulink linkID="1342128" linkType="Reference"&gt;1342128&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;Ceftriaxone was approved in Japan in June 1986, and subsequently launched in August 1986 [&lt;ulink linkID="853283" linkType="Reference"&gt;853283&lt;/ulink&gt;], [&lt;ulink linkID="1342132" linkType="Reference"&gt;1342132&lt;/ulink&gt;]. By June 2004, ceftriaxone had been approved in Japan for the additional indications of infections caused by N gonorrhoeae, pharyngitis, urethritis, cervicitis, pelvic inflammatory disease, epididymitis and rectitis [&lt;ulink linkID="561384" linkType="Reference"&gt;561384&lt;/ulink&gt;]. In November 2007, ceftriaxone (iv, 0.5 and 1 g; iv drip bag, 1 g) was granted Japanese approval for the once daily treatment of pediatric patients [&lt;ulink linkID="853283" linkType="Reference"&gt;853283&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;By July 2011, the product had been launched in China [&lt;ulink linkID="1211988" linkType="Reference"&gt;1211988&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Commonwealth of Independent States&lt;/subtitle&gt;By November 2010, ceftriaxone had been launched in Russia for the peri-operative prophylaxis of infections [&lt;ulink linkID="1401646" linkType="Reference"&gt;1401646&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In April 2008, ceftriaxone was approved in Taiwan for bacterial infections [&lt;ulink linkID="1534693" linkType="Reference"&gt;1534693&lt;/ulink&gt;], [&lt;ulink linkID="1527464" linkType="Reference"&gt;1527464&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By November 2012, intravenous and intramuscular injection formulations of the drug were approved in Brazil as Rocefin  [&lt;ulink linkID="1647989" linkType="Reference"&gt;1647989&lt;/ulink&gt;]. By November 2017, the drug had been launched in Brazil [&lt;ulink linkID="2136074" linkType="Reference"&gt;2136074&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In October 2000, a multicenter, randomized, open-label, parallel-group, phase IV study (&lt;ulink linkID="10498" linkType="Protocol"&gt;NCT00374959&lt;/ulink&gt;; TABASCO) began in Spain to assess the safety and efficacy of   ceftriaxone compared with continuous aspiration of subglottic content for the prevention of early-onset ventilator-associated pneumonia (n = 80). The primary endpoint was the cumulative incidence of early-onset ventilator-associated pneumonia. The study completed in October 2003 [&lt;ulink linkID="1342081" linkType="Reference"&gt;1342081&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;Two US studies were performed to compare the efficacy of a single im dose of ceftriaxone with a 10 day course of either &lt;ulink linkID="44284" linkType="Drug"&gt;amoxicillin + clavulanate&lt;/ulink&gt; or &lt;ulink linkID="44363" linkType="Drug"&gt;trimethoprim + sulfamethoxazole&lt;/ulink&gt; in pediatric patients with acute otitis media. Compared with amoxicillin + clavulanate, ceftriaxone demonstrated lower clinical efficacy at both day 14 and 28 (clinical efficacy rates of 74 and 58% at days 14 and 28, respectively, compared with 82 and 67% for amoxicillin  + clavulanate). In the second study, ceftriaxone was found to have equivalent efficacy to trimethoprim + sulfamethoxazole at days 14 and 28, demonstrating clinical efficacy rates of 54 and 35% at days 14 and 28, respectively, compared with 60 and 45% for trimethoprim + sulfamethoxazole [&lt;ulink linkID="1260723" linkType="Reference"&gt;1260723&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="453">Pharyngitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="227">Neisseria gonorrhoeae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2437">Empyema</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2525">Cellulitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1439">Providencia infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="227">Neisseria gonorrhoeae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-12-31T00:00:00.000Z</StatusDate><Source id="1342128" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1983-12-31T00:00:00.000Z</StatusDate><Source id="1128379" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1393">Bacteroides infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-15T00:00:00.000Z</StatusDate><Source id="1401646" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-03-19T00:00:00.000Z</StatusDate><Source id="1348407" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3886">Lung abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1434">Citrobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-04-30T00:00:00.000Z</StatusDate><Source id="1366675" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-04-30T00:00:00.000Z</StatusDate><Source id="1366675" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-04-30T00:00:00.000Z</StatusDate><Source id="1366675" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-12-31T00:00:00.000Z</StatusDate><Source id="1342128" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-08T00:00:00.000Z</StatusDate><Source id="2136074" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2951">Urethritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3081">Abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="309">Staphylococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="573">Corneal ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-12-31T00:00:00.000Z</StatusDate><Source id="1342128" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1487">Acute bronchitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3819">Bartholinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-12-31T00:00:00.000Z</StatusDate><Source id="1342128" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1438">Proteus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1983-12-31T00:00:00.000Z</StatusDate><Source id="1128379" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="1527464" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="706">Prophylaxis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-12-31T00:00:00.000Z</StatusDate><Source id="1342128" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-12-31T00:00:00.000Z</StatusDate><Source id="1342128" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-12-31T00:00:00.000Z</StatusDate><Source id="1342128" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3653">Uterus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3314">Prevotella infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3263">Morganella morganii infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1983-12-31T00:00:00.000Z</StatusDate><Source id="1128379" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-15T00:00:00.000Z</StatusDate><Source id="1401646" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1393">Bacteroides infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1440">Serratia infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-15T00:00:00.000Z</StatusDate><Source id="1401646" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-15T00:00:00.000Z</StatusDate><Source id="1401646" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1503">Proctitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="638">Klebsiella infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-15T00:00:00.000Z</StatusDate><Source id="1401646" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1982-12-31T00:00:00.000Z</StatusDate><Source id="1342081" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1796">Epididymitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3140">Pelvic inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3820">Cervicitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-15T00:00:00.000Z</StatusDate><Source id="1401646" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2019">Cholecystitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-12-31T00:00:00.000Z</StatusDate><Source id="1342128" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-07-21T00:00:00.000Z</StatusDate><Source id="1211988" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-04-30T00:00:00.000Z</StatusDate><Source id="1366675" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-04-30T00:00:00.000Z</StatusDate><Source id="1366675" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2345">Tonsillitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="452">Peritonitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2216">Cholangitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1137333">Taiyo Pharmaceuticals Industry</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2339">Laryngitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="638">Klebsiella infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1440">Serratia infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="3140">Pelvic inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1075">Haemophilus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="309">Staphylococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-11-18T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1437">Morganella infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="428">Clostridium infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="227">Neisseria gonorrhoeae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1438">Proteus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1453">Acinetobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1811">Neisseria meningitidis meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="706">Prophylaxis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1455">Moraxella catarrhalis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-09T00:00:00.000Z</StatusDate><Source id="2033651" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-05-29T00:00:00.000Z</StatusDate><Source id="1342124" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1434">Citrobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3653">Uterus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2339">Laryngitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3140">Pelvic inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="227">Neisseria gonorrhoeae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2216">Cholangitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3819">Bartholinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2345">Tonsillitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1796">Epididymitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="573">Corneal ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3263">Morganella morganii infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2525">Cellulitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="638">Klebsiella infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1440">Serratia infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3886">Lung abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1393">Bacteroides infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2951">Urethritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="453">Pharyngitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1503">Proctitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3081">Abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="452">Peritonitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3314">Prevotella infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1438">Proteus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2019">Cholecystitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1487">Acute bronchitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="309">Staphylococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3820">Cervicitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1439">Providencia infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2437">Empyema</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2109489" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1982-05-27T00:00:00.000Z</StatusDate><Source id="1128379" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1986-03-01T00:00:00.000Z</StatusDate><Source id="1342124" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-09-30T00:00:00.000Z</StatusDate><Source id="1342128" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1986-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1984-03-02T00:00:00.000Z</StatusDate><Source id="1348407" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1984-06-04T00:00:00.000Z</StatusDate><Source id="1433734" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1984-05-24T00:00:00.000Z</StatusDate><Source id="1441117" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-04-25T00:00:00.000Z</StatusDate><Source id="1454964" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-04-15T00:00:00.000Z</StatusDate><Source id="1534693" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1075">Haemophilus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1440">Serratia infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1455">Moraxella catarrhalis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="309">Staphylococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="638">Klebsiella infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1437">Morganella infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1453">Acinetobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1438">Proteus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="227">Neisseria gonorrhoeae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3140">Pelvic inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="554">Bone and joint infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="428">Clostridium infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1811">Neisseria meningitidis meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="706">Prophylaxis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-06-30T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="227">Neisseria gonorrhoeae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="561384" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="453">Pharyngitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="561384" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2951">Urethritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="561384" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3140">Pelvic inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="561384" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1796">Epididymitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="561384" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1503">Proctitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="561384" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2339">Laryngitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1986-08-31T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2345">Tonsillitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1487">Acute bronchitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3886">Lung abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2437">Empyema</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3820">Cervicitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="452">Peritonitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3081">Abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2019">Cholecystitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2216">Cholangitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3819">Bartholinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3653">Uterus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="573">Corneal ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2525">Cellulitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="309">Staphylococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1434">Citrobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="638">Klebsiella infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1440">Serratia infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1438">Proteus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3263">Morganella morganii infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1439">Providencia infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1393">Bacteroides infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3314">Prevotella infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-30T00:00:00.000Z</StatusDate><Source id="1342132" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1984-12-21T00:00:00.000Z</StatusDate><Source id="949289" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1050182">moksha8 Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1071457">Eastpharma Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1152834">Taiyo Holdings Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cn1c(nc(=O)c(n1)[O-])SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/c4csc(n4)N)SC2)C(=O)[O-].[Na+].[Na+]</Smiles><Smiles>Cn1c(nc(=O)c(=O)[nH]1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/c4csc(n4)N)SC2)C(=O)O</Smiles></StructureSmiles><Deals><Deal id="150093" title="moksha8 to commercialize Roche's therapeutics against CNS disease, anti-infectives, cardiovascular disease, pain in Brazil and Mexico"></Deal><Deal id="244049" title="Taiyo to manufacture and market Chugai's 13 long-term listed products          "></Deal><Deal id="249252" title="Eastpharma to distribute Roche's products for cardiovascular and CNS treatments in Turkey"></Deal></Deals><PatentFamilies><PatentFamily id="100957" number="EP-00045525" title="Cephalosporin derivatives and process for their preparation."></PatentFamily><PatentFamily id="1066306" number="WO-2004037833" title="Process for the preparation of cephalosporin antibiotics"></PatentFamily><PatentFamily id="1067618" number="WO-2005040175" title="Process for the preparation of cephem carboxylic acids"></PatentFamily><PatentFamily id="108145" number="US-07470786" title="Method for manufacture of ceftriaxone sodium"></PatentFamily><PatentFamily id="1086772" number="WO-2010014888" title="Methods of enhancing opsonophagocytosis in response to a pathogen"></PatentFamily><PatentFamily id="1180923" number="CN-101418015" title="Phosphorylated ceftriaxone derivatives"></PatentFamily><PatentFamily id="1195135" number="CN-102559829" title="Synthesis method for crude ceftriaxone sodium salt"></PatentFamily><PatentFamily id="1235058" number="WO-2005019227" title="Process for the preparation of cephalosporin antibiotic"></PatentFamily><PatentFamily id="1240248" number="WO-09850576" title="Betaines as adjuvants to susceptibility testing and antimicrobial therapy"></PatentFamily><PatentFamily id="1259999" number="WO-2012036585" title="Pharmaceutical composition with antimicrobial activity for parenteral administration and process for preparing same"></PatentFamily><PatentFamily id="1320678" number="KR-00361829" title="Method for preparing ceftriaxone from reactive organic acid derivatives which is able to prepare and isolate cephem derivatives useful as antibiotics"></PatentFamily><PatentFamily id="133661" number="KR-01164401" title="Method to detect extended-spectrum β-lactamases and AmpC β-lactamases using broth microdilution method"></PatentFamily><PatentFamily id="136264" number="CN-01404834" title="Synergestic antibiotic composition comprising third generation cephalosporin antibiotics cefatriaxone sodium and beta-lactamasae inhibitor sulbactam"></PatentFamily><PatentFamily id="1398460" number="CN-01679585" title="Antibacterial medicinal composition"></PatentFamily><PatentFamily id="1410066" number="CN-202052337" title="Ceftriaxone mother liquor rectifying device"></PatentFamily><PatentFamily id="1437063" number="WO-2004048551" title="Target for therapy of cognitive impairment"></PatentFamily><PatentFamily id="1462747" number="WO-2004046153" title="Prodrug esters of ceftriaxone"></PatentFamily><PatentFamily id="1481175" number="US-20090214600" title="Methods and compositions for gastric resistant oral formulations for intestinal delivery"></PatentFamily><PatentFamily id="148959" number="US-05089490" title="Cephem Derivatives"></PatentFamily><PatentFamily id="1513078" number="WO-2006085337" title="Parenteral combination therpy for infective conditions with drug resistant bacterium"></PatentFamily><PatentFamily id="1538658" number="IN-00184690" title="Process for the preparation of cephalosporin antibiotics"></PatentFamily><PatentFamily id="1567396" number="EP-00211434" title="Rectal Dosage Forms For Beta-Lactam Antibiotics"></PatentFamily><PatentFamily id="157393" number="WO-2010124601" title="Method for producing injectable preparation containing ceftriaxone sodium and tazobactam sodium"></PatentFamily><PatentFamily id="1613532" number="RU-02391105" title="Method of treating pneumonia"></PatentFamily><PatentFamily id="1652685" number="US-05070195" title="Ring-Opening Process For Preparation Of 2-Chlorosulfinyl Azetidinones"></PatentFamily><PatentFamily id="1692039" number="WO-2006059344" title="Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection"></PatentFamily><PatentFamily id="1733490" number="WO-2004076675" title="Glutamate transport modulatory compounds and methods"></PatentFamily><PatentFamily id="1745542" number="RU-02348406" title="Method of treatment of bacterial purulent meningitis in children"></PatentFamily><PatentFamily id="1756460" number="TW-00378211" title="Method of producing and analyzing ca-ceftriaxone"></PatentFamily><PatentFamily id="1773333" number="RU-02402330" title="Method of treating sinusites"></PatentFamily><PatentFamily id="1805895" number="WO-03004477" title="1,3,4-Oxadiazol-2-yl thioesters and their use for acylating 7-aminocephalosporins"></PatentFamily><PatentFamily id="1840406" number="CN-01857225" title="Aseptic injection preparation containing ceftriaxone sodium and lidocaine hydrochloride"></PatentFamily><PatentFamily id="1849686" number="WO-2008041100" title="Improved process for the preparation of cephalosporin antibiotics"></PatentFamily><PatentFamily id="1862874" number="EP-00152896" title="Suppositories containing ceftriaxone."></PatentFamily><PatentFamily id="1928788" number="CN-102198144" title="Synergetic method for bacterial inhibition of ceftriaxone sodium by chitosan"></PatentFamily><PatentFamily id="1937500" number="JP-60067413" title="Composition For Rectal Administration"></PatentFamily><PatentFamily id="2019219" number="EP-00553792" title="Process for the preparation of the disodium salt hemiheptahydrate of ceftriaxone."></PatentFamily><PatentFamily id="2046712" number="RU-02375061" title="Integrated therapy of stomach cancer"></PatentFamily><PatentFamily id="2116816" number="UA-00019152" title="Method for treating destructive pancreatitis"></PatentFamily><PatentFamily id="2125837" number="WO-00063214" title="Beta-lactam production"></PatentFamily><PatentFamily id="2199775" number="EP-00806424" title="Process for producing cephalosporin antibiotics."></PatentFamily><PatentFamily id="2210098" number="US-07071329" title="Process for preparing cephalosporins with salified intermediate"></PatentFamily><PatentFamily id="2228758" number="IN-200503182" title="Ceftriaxone sodium and tazobactam clavulanate combination in fixed injectable dosage form"></PatentFamily><PatentFamily id="2270850" number="WO-2008157308" title="A zwitterion solution for low-volume therapeutic delivery"></PatentFamily><PatentFamily id="23263" number="US-05739346" title="Dimethyl formiminium chloride chlorosulphate derivatives useful as intermediates for producing cephalosporins."></PatentFamily><PatentFamily id="2372260" number="CN-201822882" title="Medical seam anastomosis nail with wound infection prevention and treatment effect"></PatentFamily><PatentFamily id="2378287" number="EP-00399094" title="Improved process for the preparation of ceftriaxone."></PatentFamily><PatentFamily id="2420763" number="RU-02464054" title="Method of complex regional lymphothropic therapy of acute othelcosis"></PatentFamily><PatentFamily id="2446143" number="CN-202526565" title="Tectorial membrane rubber plug and medicine bottle is of tectorial membrane rubber plug"></PatentFamily><PatentFamily id="2456956" number="CN-102863401" title="Medicine intermediate dm production new process"></PatentFamily><PatentFamily id="245848" number="KR-00229174" title="Process For Preparation Of Sodium Ceftriaxone"></PatentFamily><PatentFamily id="2496465" number="WO-2013042122" title="Beta-lactam compounds for enhancing T cell-mediated immune responses"></PatentFamily><PatentFamily id="2509630" number="CN-102993215" title="Preparation method of ceftriaxone sodium crystal and evaluate method of ceftriaxone sodium aqueous solution turbidity"></PatentFamily><PatentFamily id="2566803" number="CN-102949712" title="A kind of treating tumour disease for chinese and western complex medicine"></PatentFamily><PatentFamily id="2574561" number="CN-103224473" title="A method of a triazine ring."></PatentFamily><PatentFamily id="2626250" number="WO-2013163766" title="Antimicrobial compositions comprising a hyaluronic acid binding peptide and a β-lactam antibiotic"></PatentFamily><PatentFamily id="2627056" number="US-09326988" title="Treatment and/or prevention of parkinson's disease dementia with ceftriaxone"></PatentFamily><PatentFamily id="2650416" number="WO-2013182647" title="Method for detecting susceptibility of microorganisms to chemical agents"></PatentFamily><PatentFamily id="2653283" number="CN-103417547" title="Applications of medicine prepared from ceftriaxone and used for curing and/or preventing dementia caused by Parkinson's disease "></PatentFamily><PatentFamily id="2661321" number="KR-01852885" title="The antibiotic composition which comprises the ceftriaxone or the pharmaceutically acceptable salt thereof, the sulbactam or the pharmaceutically acceptable salt thereof, and 2&amp;#8213; hydroxyethyl 12&amp;#8213; hydroxyocta decanoate"></PatentFamily><PatentFamily id="2678583" number="WO-2014025681" title="Devices and methods for wearable injection guides"></PatentFamily><PatentFamily id="2683135" number="WO-2014027697" title="Anti-pneumococcal surface protein (Psp) monoclonal antibody"></PatentFamily><PatentFamily id="2686946" number="CN-103446058" title="One medicine composition for injection of ceftriaxone sodium and lidocaine hydrochloride injection of 1%"></PatentFamily><PatentFamily id="2809341" number="CN-103908673" title="Ceftriaxone drug combination"></PatentFamily><PatentFamily id="2828278" number="CN-104130273" title="A method for synthesizing ceftriaxone"></PatentFamily><PatentFamily id="2828280" number="CN-104130271" title="No valid title"></PatentFamily><PatentFamily id="2830239" number="WO-2014184252" title="Use of clonazepam in combination with antibiotic in the treatment of bacterially induced meningitis"></PatentFamily><PatentFamily id="2901927" number="CN-104341435" title="Refining method of ceftriaxone sodium"></PatentFamily><PatentFamily id="3033876" number="CN-104887621" title="Ceftriaxone sodium and sodium low carrier medicine composition for children"></PatentFamily><PatentFamily id="3040683" number="CN-104926690" title="A recovery and refining method and device for synthesizing ceftriaxone sodium in acetonitrile"></PatentFamily><PatentFamily id="3059000" number="US-09540369" title="Use of kinase inhibitors to increase the susceptibility of gram positive bacteria to beta lactam antibiotics"></PatentFamily><PatentFamily id="3065246" number="WO-2015171225" title="Identification of novel anti-persister activity for &lt;i&gt;Borrelia burgdorferi&lt;/i&gt;"></PatentFamily><PatentFamily id="3077095" number="CN-105017243" title="A photo-degradation product of ceftriaxone sodium and preparation method and analyzing and detecting method thereof"></PatentFamily><PatentFamily id="3082608" number="RU-02580247" title="Method of increase of bacteria adhesion to vaginal epithelial cells"></PatentFamily><PatentFamily id="3098931" number="CN-105148277" title="Chinese medicine compound medicine preparation used for the false film character enteritis"></PatentFamily><PatentFamily id="3183360" number="CN-105521486" title="Ureter sigmoid anastomosis care compositions and methods for preparation"></PatentFamily><PatentFamily id="3197213" number="CN-105585581" title="Method for synthesizing ceftriaxone sodium"></PatentFamily><PatentFamily id="3199661" number="WO-2016086161" title="Intestinal microbiota and GvHD"></PatentFamily><PatentFamily id="3247186" number="UA-00090234" title="Method for the conservative treatment of abruptly detected renal failure"></PatentFamily><PatentFamily id="3315715" number="RU-02593901" title="Method for prevention of pyoinflammatory complications following surgery in maxillofacial area"></PatentFamily><PatentFamily id="3336457" number="UA-00043325" title="Method for complex treatment of patients with syndrome of diabetic foot at stage of pyo-necrotic alterations"></PatentFamily><PatentFamily id="3340419" number="US-20150105271" title="Biomarkers for increased risk of drug-induced acute hypersensitivity syndrome"></PatentFamily><PatentFamily id="3346149" number="CN-105327405" title="For loading bracket for treating cervicitis and its preparation method"></PatentFamily><PatentFamily id="3349692" number="CN-104535730" title="For detection of food cephalosporin antibiotic residual and antibody chip kit and method"></PatentFamily><PatentFamily id="3353592" number="WO-2016141216" title="Pharmacy workflow management with integrated alerts"></PatentFamily><PatentFamily id="3428672" number="EP-03085383" title="A pharmaceutical composition comprising erythropoietin and ceftriaxone and a use thereof in the manufacture of a medicament for the treatment of parkinson's disease dementia"></PatentFamily><PatentFamily id="3432649" number="RU-02599491" title="Use of subcutaneous interstitial injection in complex therapy of contusion syndrome of mediastinal organs and ventilator-associated pneumonia"></PatentFamily><PatentFamily id="3451281" number="CN-105116063" title="A multiplex detection method of cephalosporin medicine residue in milk product"></PatentFamily><PatentFamily id="3473952" number="US-10287616" title="Label free biosensors, Gram-negative bacteria detection, and real-time and end point determination of antibiotic effects"></PatentFamily><PatentFamily id="3479222" number="WO-2016201342" title="Sepsis treatment and related compositions methods and systems"></PatentFamily><PatentFamily id="3519375" number="CN-106317079" title="A ceftriaxone-solid phase synthesis method"></PatentFamily><PatentFamily id="3538601" number="IN-201502190" title="Synergistic combination of two drugs, useful for treating neurological disorders including parkinsonism and parkinsonism induced depression in humans, comprises bupropion and ceftriaxone"></PatentFamily><PatentFamily id="3538946" number="CN-106353388" title="MCM-41 for preparing modified carbon paste electrode and ceftriaxone for electrochemical detection"></PatentFamily><PatentFamily id="353954" number="MD-00000118" title="Method for treating the chronic obstructive pulmonary disease to persons of elderly age"></PatentFamily><PatentFamily id="3606714" number="WO-2016057744" title="Beta-lactamase formulations and uses thereof"></PatentFamily><PatentFamily id="361232" number="WO-2004000848" title="Process for the conversion of penam ring system to cepham ring system"></PatentFamily><PatentFamily id="3613458" number="CN-106562971" title="A preparation method of ceftriaxone sodium powder injection preparation"></PatentFamily><PatentFamily id="363471" number="WO-2011012965" title="Improved process for preparation of ceftriaxone disodium hemiheptahydrate"></PatentFamily><PatentFamily id="364467" number="US-20040242863" title="Preparation of cefalosporins intermediates and conversion of said intermediates into active compound precursors."></PatentFamily><PatentFamily id="3736373" number="MD-00001155" title="Minimally invasive mathod for treating spontaneous ascites-peritonitis in decompensated liver cirrhosis"></PatentFamily><PatentFamily id="3749138" number="RU-02557957" title="Method of treating patients with chronic endometritis and tubal and peritoneal infertility factor"></PatentFamily><PatentFamily id="3749324" number="WO-2017132770" title="Wound dressings and methods"></PatentFamily><PatentFamily id="3765092" number="WO-2017140770" title="Means and methods for treating bacterial infections"></PatentFamily><PatentFamily id="3787906" number="EP-03216873" title="Combination of structural variations and single nucleotide changes in one statistical model for improved therapy selection"></PatentFamily><PatentFamily id="3877668" number="CN-107412167" title="Production method of ceftriaxone sodium for injection"></PatentFamily><PatentFamily id="390403" number="US-05347000" title="Process For The Preparation Of 2-Chlorosulfinylazetidinone"></PatentFamily><PatentFamily id="3993816" number="CN-104558187" title="Monoclonal antibody and enzyme-linked immune method and reagent kit for detecting cephalosporins antibiotics"></PatentFamily><PatentFamily id="4004146" number="CN-107857741" title="New synthesis technique of 2-aminothiazole-4-methylisoximiano acid"></PatentFamily><PatentFamily id="4031399" number="CN-107955021" title="A low impurity production method of ceftriaxone sodium"></PatentFamily><PatentFamily id="4062789" number="CN-108047253" title="A compound of ceftriaxone sodium crystal"></PatentFamily><PatentFamily id="4095867" number="WO-2018111630" title="Rnase for improved microbial detection and antimicrobial susceptibility testing"></PatentFamily><PatentFamily id="4173946" number="CN-108440569" title="Preparation method of spherical crystalline of ceftriaxone sodium"></PatentFamily><PatentFamily id="4221130" number="WO-2018184073" title="Method for testing antimicrobial susceptibility"></PatentFamily><PatentFamily id="4240310" number="WO-2018195343" title="Assay for the comprehensive identification of antibiotic sensitivity"></PatentFamily><PatentFamily id="4261952" number="WO-2018209307" title="Methods for detecting dysbiosis and treating subjects with dysbiosis"></PatentFamily><PatentFamily id="4292360" number="WO-2018219187" title="Application of cephalosporin antibiotics in preparation of medicine for preventing/treating pulmonary arterial hypertension"></PatentFamily><PatentFamily id="4329380" number="WO-2019006459" title="Methods and compositions related to STK1-targeted small molecules as antibiotic resistance breakers"></PatentFamily><PatentFamily id="4333773" number="CN-109053627" title="Ceftriaxone dichloromethane mother liquor in 2-comprehensive recycling method of mercapto benzothiazole, triethylamine and dichloromethane"></PatentFamily><PatentFamily id="4339098" number="CN-109010280" title="Preparation method of ceftriaxone sodium powder injection preparation for injection"></PatentFamily><PatentFamily id="4380141" number="EP-03434273" title="Ceftriaxone for use in the treatment of dementia with lewy bodies"></PatentFamily><PatentFamily id="4475494" number="WO-2019075264" title="Antibiotic susceptibility of microorganisms and related compositions, methods and systems"></PatentFamily><PatentFamily id="4549802" number="WO-2019118330" title="Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear"></PatentFamily><PatentFamily id="475711" number="WO-2005041978" title="Neuroprotection with beta-lactam compounds"></PatentFamily><PatentFamily id="566743" number="WO-2010057647" title="Methods and compositions for the diagnosis and treatment of diabetes"></PatentFamily><PatentFamily id="574144" number="WO-2005105813" title="Improved process for the manufacture of ceftriaxone sodium"></PatentFamily><PatentFamily id="579371" number="CN-01442144" title="Antibacterial composite medicine"></PatentFamily><PatentFamily id="589135" number="CN-101747347" title="Low crystal-water ceftriaxone crystals and preparation method thereof"></PatentFamily><PatentFamily id="606924" number="JP-02279627" title="Antibacterial Composition"></PatentFamily><PatentFamily id="668148" number="US-20090075967" title="Deuterium-enriched ceftriaxone"></PatentFamily><PatentFamily id="685766" number="US-05318781" title="Absorption enhancement of antibiotics."></PatentFamily><PatentFamily id="724154" number="EP-00842937" title="Process for the preparation of the cephalosporin derivatives cefotaxime and ceftriaxone."></PatentFamily><PatentFamily id="750828" number="RU-02454252" title="Method for prevention of suppurative septic complications (SSC) in colon surgeries"></PatentFamily><PatentFamily id="790362" number="US-07919113" title="Dispersible concentrate lipospheres for delivery of active agents"></PatentFamily><PatentFamily id="829092" number="US-04758556" title="Cephem derivatives"></PatentFamily><PatentFamily id="866867" number="WO-02053563" title="Novel Thioester Derivatives Of Thiazolyl Acetic Acid And Their Use In The Preparation Of Cephalosporin Compounds"></PatentFamily><PatentFamily id="895086" number="MD-00000398" title="Method for stimulating the resorption of peritoneal processes by reactivation of lymphocirculation in patients with hepatic cirrhosis"></PatentFamily><PatentFamily id="931275" number="RU-02348411" title="Method of leukoencephalitis treatment in children"></PatentFamily><PatentFamily id="948253" number="EP-00556768" title="New Process For The Production Of Ceftriaxone"></PatentFamily><PatentFamily id="953869" number="KR-00697312" title="Composition comprising ceftriaxone showing excellent STAT3 inhibition activity for treating cancer"></PatentFamily><PatentFamily id="975331" number="IT-01230612" title="Procedimento Per La Preparazione Di Ceftriaxone E I Suoi Sali Farmaceuticamente Accettabili"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>29</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>30</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>43</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>15</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>16</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rheinisch-Westfaelische Technische Hochschule Aachen" id="1005607"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="North China Pharmaceutical Group Corp (NCPC)" id="1005667"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmachim Engineering SRL" id="1007095"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Synthetic Biolog Dev" id="1007155"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hallym University" id="1008136"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Peking University" id="1009044"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Integrated Research Technology LLC" id="1010119"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National Institutes for food and drug Control" id="1010498"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Oakland University" id="1011810"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emergent BioSolutions Inc" id="1011990"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Synthetic Biologics Inc" id="1017428"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jinan University (Guangdong)" id="1019449"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Venus Remedies Ltd" id="1021105"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Huazhong Agricultural University" id="1021601"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nectar Lifesciences Ltd" id="1027927"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harbin Pharmaceutical Group Co Ltd" id="1028437"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chung Shan Medical University" id="1031584"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kirin Holdings Co Ltd" id="1037687"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protia LLC" id="1043660"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tongji University" id="1049164"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="South China University of Technology (Scut)" id="1049465"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioSym Technologies of Iowa LLC" id="1050272"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Union Korea Pharm Co Ltd" id="1054330"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China National Pharmaceutical Group Corporation" id="1055632"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Curetis AG" id="1055723"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sihuan Pharmaceutical Holdings Group Ltd" id="1056556"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Xinquan Pharmaceutical Intermediates Ltd" id="1056702"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Haikou Qili Pharmaceutical Co Ltd" id="1057824"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Altermune Technologies Llc" id="1057936"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ural State Medical Academy" id="1062631"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="TL &amp; GM Chemical Co" id="1063413"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xiangbei Welman Pharmaceutical Co Ltd" id="1065449"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stem Cell Medicine Ltd" id="1066060"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Elwha LLC" id="1068875"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Lingkang Pharmaceutical Group Co Ltd" id="1069218"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gosudarstvennoe Obrazovatel 'noe Uchrezhdenie Vysshego Professional' nogo Obrazovanija Kurskij Gosuda Med Uni Federal Nog" id="1069497"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nicolae Testemitanu State University of Medicine and Pharmacy" id="1069658"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institute of the Federal Security Service of Russia (Nizhny Novgorod)" id="1070808"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Federal State Institution Research Institute of Childhood Infections" id="1070989"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanxi Weiqida Pharmaceutical Co., Ltd" id="1071581"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Health Biotech Pvt Ltd" id="1072038"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Omsk State Medical Academy" id="1072440"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayesian Guangzhou Pharmaceutical Co Ltd" id="1072855"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Youcare Pharmaceutical Group Co Ltd" id="1073268"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wanchang Tongtai Pharmaceutical Co Ltd" id="1074126"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dawnrays Pharmaceutical (Holdings) Limited" id="1074359"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Korea Pharma Co Ltd" id="1076422"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Research Institute for Physico-Chemical Medicine of the Federal Medical-Biological Agency of the Russian Federation" id="1076467"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Asia Pioneer Pharmaceutical Co Ltd" id="1076693"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Yongtian Medicine Research Institute Co Ltd" id="1077725"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Red Sun Pharmaceutical Co Ltd" id="1079208"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sichuan Pharmaceutical Inc" id="1083123"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Heilongjiang University" id="1083713"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Idmic Sa" id="1090965"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astrakhan State Medical Academy" id="1093464"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cnj Holdings Inc" id="1096881"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zaporozhye State Medical University" id="1097886"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Taiyuan Jinyuan Xingyuan Chemical Plant" id="1098762"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="WenZhou Jiali Chemical Co Ltd" id="1105444"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Severe Adverse Event (Sae) Consortium" id="1108106"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Handian Pharmaceutical Co Ltd" id="1111354"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Changdian Pharmaceutical Co Ltd" id="1111685"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chitkara University" id="1120636"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Nine Heaven High-Tech Co Ltd" id="1121687"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Purinergix LLC" id="1122383"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institute of Cellular and Intracellular Symbiosis  , Ural Branch of the Russian Academy of Sciences" id="1125638"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangzhou Zhengfu Detection Technology Co Ltd" id="1129025"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Raygene Biotech International Inc" id="1138425"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fed Gosudarstvennoe Byudzhetnoe Nauchnoe Uchrezhdenie Nauchno-Issledovatelskij Inst Klinicheskoj" id="1139641"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Or Science Inc" id="1152107"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pathnostics" id="1154087"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BrainX Corporation" id="1161090"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MicrobeDx Inc" id="1164764"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emalex Biosciences Inc" id="1170011"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Jincheng Pharmaceutical Group Co., Ltd." id="1172516"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Ningrui Biochemical Technology Co Ltd" id="1174260"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Siolta Therapeutics" id="1175387"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Hoffen Pharmaceutical Co Ltd" id="1176898"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou Dawnrays Pharmaceutical Co. Ltd." id="1181135"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Baxter International Inc" id="14437"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Commissariat a l`Energie Atomique" id="15529"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Development Center for Biotechnology" id="15669"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Western Australia" id="16842"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kyoto Pharmaceutical Industries Ltd" id="17723"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SBD Synthetic and Biological Developments SrL" id="19684"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Berlin Free University" id="20535"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of California" id="20547"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Columbia University" id="20559"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hebrew University of Jerusalem" id="20586"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Hawaii" id="20591"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johns Hopkins University" id="20596"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universita degli Studi di Milano" id="20625"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ohio State University" id="20649"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Pittsburgh" id="20659"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universitat des Saarlandes" id="20672"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wayne State University" id="20702"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="California Institute of Technology" id="21070"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>15</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>15</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ACS Dobfar SpA" id="21883"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lupin Ltd" id="21932"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Memorial Sloan-Kettering Cancer Center" id="22122"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="LG Chem Ltd" id="22235"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Forschungszentrum Borstel Zentrum fur Medizin und Biowissenschaften" id="22973"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Russian Academy of Sciences" id="24837"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Istituto Scientifico H San Raffaele" id="25126"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Korea Research Institute of Bioscience and Biotechnology" id="25145"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hichem Pharma SpA" id="25604"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wockhardt Ltd" id="27614"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Orchid Pharma Ltd" id="27798"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Lubeck" id="DOL1000147"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Wisconsin-Madison" id="DOL1000742"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>